ACKNOWLEDGEMENTS
The trial was partially funded by a National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP) PBTC U01 Grant: 2UM1CA081457 (UM1). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Partial funding was also provided by MSKCC Core Grant (P30 CA008748) and by the American Lebanese Syrian Associated Charities (ALSAC) which provides funding and infrastructure support for the PBTC Operations Core personnel. Pfizer provided Palbociclib and financial support for trial conduct, patient research costs, operations costs and correlative studies. Pfizer reviewed the manuscript but did not have a direct role in trial design, patient recruitment, data collection, analyses or manuscript preparation.